Efficacy Of Three Kinds Of TNF-alpha Antagonists Herapy In Ankylosing Spondylitis

Objective: To compare the dynamic non-biological DMARDS andbiological DMARDS [tumor necrosis factor–α antagonists] treatment ofankylosing spondylitis efficacy dynamic,analysis of the current clinicalapplication of three different pre-TNF-α antagonists efficacy,explore differentkinds of TNF-α antagonists on patients with ankylosing spondylitis inflammatoryindicators.Methods: Collected80cases AS patients in Jilin Provincial China-Japanunion Hospital division of Rheumatology hospital from January2010-December2013. Patients were divided into four different groups [slow-actingantirheumatic drug group (DEMARDs), Hideo Lee celecoxib group, etanercept,adalimumab group] according to the medication, observed four groups ofpatients before and after treatment (two weeks) clinical symptoms, signs andlaboratory findings before and after treatment to assess disease activity inpatients with inflammatory markers [erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), platelet count (PLT), mean platelet volume (MPV),serum albumin (ALB), prealbumin (PALB) and the duration of morning stiffness,patient visual analogue scale (patients VAS), Bath tonic spondylitis diseaseActivity Index (BASDAI), ankylosis spondylitis disease activity score (ASDAS)]and other changes.The results: CRP and BASDAI, ASDAS positive correlation, which werethe biggest change in the treatment of early, can be used as early indicators ofefficacy. ESR and BASDAI, ASDAS positive correlation, PLT was positivelycorrelated with BASDAI. Effects of infliximab on CRP early in more than adalimumab (p value <0.05), the impact of ESR, PALB greater thanetanercept (p value <0.05). Adalimumab in Early PALB affect more thanetanercept (p value <0.05). Three kinds of TNF-α antagonists in the early nosignificant difference (p>0.05) effect on the PLT, MPV. Adalimumab group,etanercept group at an early influence on patient VAS score greater thaninfliximab group (p value <0.05), all three TNF-α antagonists Early morningstiffness, BASDAI, ASDAS no significant difference in the impact (p>0.05).Conclusion: Three TNF-α antagonist therapy in ankylosing spondylitisearly efficacy clinical symptoms, signs and laboratory tests are different, andstatistically significant.